CiteScore measures average citations received per document published in the serial.
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Overview | |
Publisher | ELSEVIER |
Language | English |
Frequency | Tri-annual |
Article Processing Charges | USD 2000 |
Publication Time | 13 |
Editorial Review Process | Anonymous peer review |
General Details | |
Language | English |
Frequency | Tri-annual |
Publication Start Year | 2019 |
Publisher URL | Visit website |
Website URL | Visit website |
Publication Details | |
Plagiarism | Visit website |
Waiver Policy | Visit website |
Publication Time | 13 |
Article Processing Charges | USD 2000 |
Editorial Review Detail | |
Editorial Team | Visit website |
Review Process | Anonymous peer review |
Review Url | Visit website |
Information for authors | |
Author instructions | Visit website |
Copyright Details | Visit website |
License type | CC BY, CC BY-NC-ND |
OA statement | Visit website |
Upload your Manuscript to get
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my Paper459 articles received 1.7k citations see all
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Vaccine: X has been in operation since 2019 till date.
Vaccine: X published with a Tri-annual frequency.
In 2023, Vaccine: X published 7 articles.
For Vaccine: X,eISSN is 2590-1362 and pISSN is2590-1362.
Citescore for Vaccine: X is 3.9.
SNIP score for Vaccine: X is 1.81.
ELSEVIER is the publisher of Vaccine: X.